Ganjehei Leila, Becker Richard C
Division of Cardiovascular Health and Disease, University of Cincinnati Medical Center, 231 Albert Sabin Way, MLC 0542, Cincinnati, OH, 45267-0542, USA.
Lung and Vascular Institute, University of Cincinnati Medical Center, Cincinnati, OH, USA.
J Thromb Thrombolysis. 2015 Nov;40(4):499-511. doi: 10.1007/s11239-015-1267-6.
Aspirin has been in use for prevention and management of cardiovascular diseases for several decades. Clinical and epidemiological literature suggests that while net benefits of aspirin in primary prevention of CVDs are less clear, the benefits of aspirin in acute scenarios and secondary prevention settings are well established. However, its optimum dosing requirements have been up for debate especially in various settings of acute coronary syndrome and stable ischemic heart disease. The role of clinician in stratifying individual risk score to achieve net clinical benefit is an important determinant of initiating aspirin therapy. The purpose of this article is to review association of aspirin and CVD in general, and to review its dosing regimens in acute settings as well as primary and secondary prevention as suggested by various established guidelines. We also aim to provide the readers an update on recent changes and current evidence based practice trends.
几十年来，阿司匹林一直用于心血管疾病的预防和管理。临床和流行病学文献表明，虽然阿司匹林在心血管疾病一级预防中的净效益尚不太明确，但阿司匹林在急性情况下和二级预防环境中的益处已得到充分证实。然而，其最佳剂量需求一直存在争议，尤其是在急性冠状动脉综合征和稳定型缺血性心脏病的各种情况下。临床医生在分层个体风险评分以实现净临床效益方面的作用是启动阿司匹林治疗的重要决定因素。本文的目的是综述阿司匹林与心血管疾病的总体关联，并根据各种既定指南回顾其在急性情况下以及一级和二级预防中的给药方案。我们还旨在向读者提供最新变化以及当前基于证据的实践趋势。
